Key opinion leaders present data, describe clinical cases, and participate in a debate of one of the greatest controversies today in the management of early breast cancer: when to use anthracycline- or nonanthracycline-containing regimens in patients with breast cancer. HER2-positive and HER2-negative cases will be explored.
| Event Date |
Details |
| Friday, December 12, 2008 |
7:30 PM - 10:00 PM
Local Time
Registration and Dinner 7:30 PM - 8:00 PM
Symposium 8:00 PM - 10:00 PM
|
Agenda
8:00 PM - 8:10 PM
Welcome and Introduction
Understanding How Treatment Choices Directly Impact the Lives of Patients
Chair: Fran Visco, JD
Insights and considerations are discussed regarding the patient's perspective on the use of anthracyclines in the adjuvant setting.
8:10 PM - 9:00 PM
Interpretations: The Role of Anthracyclines in the Adjuvant Treatment of Breast Cancer
Faculty: Dennis J. Slamon, MD, PhD; Mark Levine, MD
Faculty members present their expert opinions regarding the use of anthracycline and non-anthracycline-containing regimens in patients with early breast cancer. Key questions to be addressed include:
-
Should anthracyclines remain the backbone of systemic therapy for all patients with adjuvant breast cancer?
-
What is the optimal regimen for patients with HER2-negative tumors?
-
What role does HER2 and topoisomerase IIα status play in determining whether or not to use an anthracycline?
9:00 PM - 9:40 PM
Applying What We Know to Clinical Case ScenariosFour specific patient cases will be presented that highlight clinical decisions based on (but not limited to) HER2 status, topoisomerase IIα expression, and the presence or absence of comorbidities.
9:40 PM - 10:00 PM
Question and Answer Session